

UC San Diego

UC San Diego Previously Published Works

Title

Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood

Permalink

<https://escholarship.org/uc/item/6cx5d192>

Authors

Desplats, Paula
Gutierrez, Ashley M
Antonelli, Marta C
et al.

Publication Date

2020-10-01

DOI

10.1016/j.neubiorev.2019.10.013

Peer reviewed



Published in final edited form as:

Neurosci Biobehav Rev. 2020 October ; 117: 232–242. doi:10.1016/j.neubiorev.2019.10.013.

Microglial memory of early life stress and inflammation: susceptibility to neurodegeneration in adulthood

Paula Desplats^{1,2}, Ashley M. Gutierrez¹, Marta C. Antonelli^{3,4}, Martin G. Frasch^{5,6}

¹Department of Neurosciences, University of California San Diego, CA, USA

²Department of Pathology, University of California San Diego, CA, USA

³Instituto de Biología Celular y Neurociencia “Prof. Eduardo De Robertis”, Facultad de Medicina, Universidad de Buenos Aires, Argentina

⁴Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Germany

⁵Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA

⁶Center on Human Development and Disability, University of Washington, Seattle, WA, USA

Abstract

We review evidence supporting the role of early life programming in the susceptibility for adult neurodegenerative diseases while highlighting questions and proposing avenues for future research to advance our understanding of this fundamental process. The key elements of this phenomenon are chronic stress, neuroinflammation triggering microglial polarization, microglial memory and their connection to neurodegeneration. We review the mediating mechanisms which may function as early biomarkers of increased susceptibility for neurodegeneration. Can we devise novel early life modifying interventions to steer developmental trajectories to their optimum?

Keywords

pregnancy stress; neuroinflammation; early life; glia; Alzheimer’s; Parkinson’s; CHRNA7; enriched environment; policy; animal models

1. Introduction

In this focused review, we propose that susceptibility to adult neurodegenerative diseases is programmed in the womb, and early postnatal preventive measures may reduce the risk. We

Address of correspondence: Martin G. Frasch, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St, Box 356460, Seattle, WA 98195, Phone: +1-206-543-5892, Fax: +1-206-543-3915, mfrasch@uw.edu.

Conflict of interest statement

The authors have declared that no conflict of interest exists

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

delineate the key mechanisms and players mediating this phenomenon, a foundation for preventive strategies. First, we discuss what are likely the most common two insults taking place during fetal development and imprinting upon fetal brain: chronic pregnancy stress and inflammation. We propose that such imprinting is mediated via the microglial plasticity resulting in memory properties and that such memory may increase susceptibility to neurodegenerative diseases in adult life. We review the animal models required for studying and testing the mechanisms. The proposed concept requires a discussion of microglial plasticity and mechanisms by which *in utero* insults influence the dynamic process of microglial-neuronal interactions in the developing brain. The role of microglia in adult neurodegenerative disorders is discussed and this concept is brought back to the perinatal origins of adult susceptibility to neurodegeneration. Finally, we discuss how our present understanding of the mechanisms of microglial memory formation may inform novel modifying treatments to steer developmental trajectories to their optimum.

2. Programming of fetal brain development by chronic stress exposure: the concept

The complex development of the nervous system is characterized by essential processes like cell proliferation, migration and differentiation that follow a tightly regulated program at well-coordinated time points to ensure the establishment of brain structures and functions (Andersen 2003). During this developmental process, the organisms may be exposed to insults and environmental influences that might be critical for later susceptibility to diseases. Several models have been proposed to explain how this exposure to insults *in utero* and/or during early postnatal stages affects the development of target organs, disrupts homeostasis and increases the risk for diseases manifested in later life. Based on his studies on adult cardiovascular disorders, Barker proposed the hypothesis of the Fetal Basis of Adult Diseases (FeBAD) (Barker 1993). FeBAD suggests that the fetus responds to the maternal health status mounting adaptive responses for survival. Stemming from Barker's hypothesis, several other models have been proposed (Gluckman and Hanson 2006, Ben-Ari 2008, Gluckman, Hanson et al. 2010) prompting Van den Bergh to formulate the hypothesis of the "Developmental Origins of Behavior, Health and Disease" (DOBH_aD), which integrates early brain and behavioral development with new insights from the field of epigenetics (Van den Bergh 2011).

Taken together, these models point to the concept that adult health and behavior are programmed *in utero*; and they are shaped postnatally throughout lifetime through new exposures. This continuous programming is mediated by epigenetic mechanisms to which we will return in Section 6.

Perinatal stress is a known powerful driver of an individual's spatiotemporal epigenome and integrative physiological responses: different cell types and organs - particularly the brain - elicit specific stress responses at different developmental stages due to genomic-/epigenomic-environmental interactions (Metz, Ng et al. 2015, Conradt, Adkins et al. 2018, Frasch, Lobmaier et al. 2018). On the integrative physiological scale in humans, chronic maternal stress in the early third trimester of gestation can program heart rate regulatory

systems in the fetus to be entrained by maternal heart rate fluctuations. This phenomenon is not seen in control subjects with low levels of stress as measured by Cohen perceived stressed scale (PSS-10) (Lobmaier S. 2019). More generally, such relative coordination and entrainment phenomena are well-described in the weakly coupled nonlinear dynamical systems, such as the complex physiological systems (Scott Kelso, Holt et al. 1981, Hoyer, Frasch et al. 2001).

Despite these pilot reports in human cohorts, much of the evidence on the effects of perinatal stress on adult life has been gathered from animal studies (Frasch, Baier et al. 2018). We believe that animal models will continue to be indispensable to investigate the alterations of glial-neuronal development under various insults, including perinatal stress, to understand their mechanistic contribution to increased susceptibility to adult neurodegenerative diseases.

3. Animal models of perinatal stress reveal links to early life neuroinflammation and neurodegeneration

The last twenty years have witnessed an exponential increase in publications related to the effect of perinatal stress on offspring neurodevelopment both in animal models and in humans (Jawahar, Murgatroyd et al. 2015, Van den Bergh, van den Heuvel et al. 2017, Frasch, Baier et al. 2018). A detailed description of the factors that might lead to perinatal stress has been summarized before (Frasch M 2017). Broadly, these factors are comprised of a vast number of modifiable and nonmodifiable influences that the mother-child dyad might experience pre- and/or postnatally. The modifiable factors include under and overnutrition, substance abuse, drugs intake, intrauterine growth restriction or infection. The nonmodifiable factors include wars, famines, and natural disasters. Perinatal stress includes both, models of *prenatal* stress (PS) (Hubacek, Pitha et al. 2000) and *postnatal* stress; the latter are often referred to as Early Life Stress (ELS) (Jawahar et al, 2015). Note that in this review we reserve the PS abbreviation to *prenatal* stress.

Animal models of PS have been designed to transfer the stress experienced by the mother to the embryo or fetus *in utero* by exposing the pregnant dam to stressors during different gestational phases (Huizink, Mulder et al. 2004, Mastorci, Vicentini et al. 2009, Bock, Wainstock et al. 2015). Similarly, animal models of ELS have been designed to mimic childhood adversities, mostly related to the quality of maternal care such as maternal neglect or maltreatment (Jawahar, Murgatroyd et al. 2015, McDonnell-Dowling and Miczek 2018).

[AQ1] Regardless of the type of stressor applied, its frequency, duration and gestational/postnatal period of application, most studies using animal models provided strong evidence that exposure to insults during the prenatal period or during early postnatal development turns the offspring vulnerable to disease in later life. The consequences of such stressors are broad and can include learning and cognitive delays, cardio-metabolic alterations, pro-inflammatory responses, neuroendocrine impairment and neurodegenerative disorders (Van den Bergh 2011, Modgil, Lahiri et al. 2014, Heim, Entringer et al. 2019). An important example of this relationship is observed in the limited nesting and bedding model (Rice et al, 2008; Walker et al, 2017), a specific paradigm of ELS related to maternal neglect and

maltreatment which was shown to exacerbate the amyloid- β ($A\beta$) plaque burden in the hippocampus and the neuroinflammatory response to $A\beta$ in aged transgenic APP/PS1 mice (Brunson, Kramar et al. 2005, Hoeijmakers, Ruijgrok et al. 2017). Conversely, enhanced maternal care after postnatal handling reduces amyloid accumulation in the hippocampus ameliorating cognitive decline in the APP^{swe}/PS1^{dE9} mouse model of Alzheimer's disease (AD) (Lesuis, van Hoek et al. 2017).

Together, these observations led to the neurodevelopmental hypothesis of neurodegenerative disorders: an unfavorable environmental input during early life shapes adult neuroplasticity that might result in neurodegenerative processes (Schaefer and Teuchert-Noodt 2016, Fanni, Gerosa et al. 2018).

This neurodevelopmental hypothesis is clearly related to the “two hits” hypothesis in which each of the environmental inputs is considered a “hit” and, after a certain latency period, a second trigger is necessary for the disease to develop (Lahiri, Maloney et al. 2009). Nowadays, the theory has gained consideration as the concept of “multiple hits” to better interpret the composite genetic and environmental interplay that contributes to the development of neurodegenerative diseases (Faa, Marcialis et al. 2014, Davis, Eyre et al. 2016, Post, Lieberman et al. 2018).

For example, prenatally stressed (“first hit”) adult rats exposed to an intrastriatal injection of 6-hydroxy-DA (6-OHDA) to damage dopaminergic neurons (“second hit”) show high levels of tyrosine hydroxylase (TH) positive cells in the ventral tegmental area (VTA) which are more susceptible to 6-OHDA. In addition, the number and asymmetry of neuronal nitric oxide synthase (nNOS)-expressing cells in the VTA and nucleus accumbens are altered in PS rats. These results suggest a deregulation between dopaminergic and nitroergic systems in the VTA of PS rats, which responded to the neurotoxic aggression by increasing the number of nNOS positive cells involved in neuroprotection of TH positive cells (Baier et al., 2014).

PS affects both neuronal and glial cells, which show severe alterations in morphology and neurotransmitter systems. Adult male offspring of stressed rat dams exhibits long-lasting astrogliosis with reduced dendritic arborization (Barros, Duhalde-Vega et al. 2006). This is accompanied by an increase of ionotropic and metabotropic glutamate receptors in the frontal cortex (FCx), striatum and hippocampus (Berger, Barros et al. 2002). In addition, there is an elevation in vesicular vGluT1-transporter in the FCx and GLT1 in hippocampus, associated with an increased glutamate uptake capacity in the FCx (Adrover, Pallares et al. 2015) and alterations in nitric oxide synthase-expressing cells (Baier, Pallares et al. 2014).

Furthermore, PS induces changes in the glutamatergic metabolism, such as reduction of glutamatergic neurotransmission in the ventral hippocampus (Marrocco, Mairesse et al. 2012) and sex-specific increase of glutamate-receptor expression (Zuena, Mairesse et al. 2008, Wang, Ma et al. 2016). In addition, enhanced microglial activation is evidenced by an increased expression of microglial markers (Slusarczyk, Trojan et al. 2015), increased number of microglial cells with large somas (Diz-Chaves, Pernia et al. 2012), and an acceleration of microglial differentiation into ramified forms in the pre-weaning offspring (Gomez-Gonzalez and Escobar 2010).

In sum, piling evidence derived from the PS animal models shows significant reprogramming of the glutamatergic-nitric oxide-microglia metabolism in prenatally stressed offspring. This supports the notion that exposure to insults during the prenatal and/or early life period may shape the vulnerability to neurodegenerative disorders in later life.

4. Microglial plasticity due to fetal and neonatal insults: a microglial memory programming mechanism for life

Microglia are the resident macrophages of the central nervous system, involved in immune surveillance; synaptic pruning and phagocytosis of misfolded protein aggregates (Heppner, Ransohoff et al. 2015).

The neuropsychological notion of memory is usually linked to the concept of neuronal plasticity, i.e., the ability of neuronal cells and neuronal ensembles to adapt to their environment, individually and collectively, and respond adaptively when re-encountering the same or similar set of stimuli. Evidence is mounting that similar mechanisms operate in glial cells, particularly microglia. Beyond their role as the “conventional macrophages of the brain,” microglia have fundamental roles in synaptogenesis (Kettenmann, Hanisch et al. 2011). As we discuss in detail in the next section, aberrant glial-neuronal interactions are important players in early stages of AD and other adult neurodegenerative diseases (Madhusudan, Vogel et al. 2013, Bilbo and Stevens 2017, Frasch, Burns et al. 2018).

It is well known that excessive activation of ionotropic glutamate receptors causes excitotoxicity and promotes cell death, underlying a potential mechanism of neurodegeneration. In addition to the excitotoxicity and inflammatory processes that characterize neurodegenerative disorders, an emergent role has recently been discussed for the nitric oxide pathways in relation to the glutamate neurotoxicity (Manucha 2017). Glutamate receptors are also expressed in microglia and it has been postulated that a dysfunctional subunit GluA2 may accelerate glutamate neurotoxicity via release of proinflammatory cytokines from microglia in neurodegenerative diseases (Noda 2016).

Overactivation of microglia with a memory of PS may inflict injury in adulthood. For example, PS paradigms such as models of depression affect the offspring later in life inducing behavioral changes in adult mice, elevated release of chemokines and a profuse microglial activation (Slusarczyk, Trojan et al. 2015). In addition, PS has been linked with an abnormal expression of the $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ nAChR) in the male PS-exposed adult brain (Baier, Pallares et al. 2015). Prenatal exposure to maternal restraint stress, a form of PS, reduced protein levels of $\alpha 7$ nAChR in the adult frontal cortex and hippocampus, key areas affected by the AD pathology (Jellinger and Attems 2013). Further studies are needed to associate cell type-specific expression of $\alpha 7$ nAChR to PS as well to neuropathological and behavioral phenotypes in mid and late adulthood.

Recent studies in mice also indicate the role of inflammation in shaping microglia and behavior in the aging offspring of stressed mothers. Early life exposure to lipopolysaccharides (LPS), a widely used model of inflammation caused by infection with gram-negative bacteria, results in differential location of activated microglia in the brain,

with sustained alterations in hippocampal microglia that become hypersensitive to inflammatory markers. These changes endure throughout adulthood and have negative effects on memory and learning (Schaafsma, Basterra et al. 2017).

In line with these LPS-based studies and independent of PS, infections of the gut may precede Parkinson's disease (PD) by years or trigger it in an experimental mouse model (Matheoud, Cannon et al. 2019, Nerius, Doblhammer et al. 2019). The latter demonstrated involvement of glial cells in the pathogenesis of the autoimmune response resulting in a PD phenotype. These findings underscore the importance of the brain-gut axis for neurodegenerative diseases and the likely multi-hit nature of their etiology. The longest brain nerve connecting brain and body is the vagus nerve, an important substrate of cholinergic signaling, including peripheral signaling via the $\alpha 7$ nAChR, the cholinergic anti-inflammatory pathway (Rosas-Ballina, Olofsson et al. 2011). This brain-body connection begins *in utero* (Garzoni, Faure et al. 2013) and interruption of the vagus nerve signaling reduces the risk for PD (Liu, Fang et al. 2017). Non-neuronal (i.e., non-vagus-nerve), humoral, lymphatic and blood-stream - mediated brain-gut pathways have also been discussed in linking enteric and cerebral homeostasis (Santos, de Oliveira et al. 2019).

In addition to gut infections, chronic oral cavity infections have also been associated with an increased risk for AD, probably mediated by resident microglia responding to chronic systemic inflammation caused by periodontitis (Kamer, Craig et al. 2008, Wu and Nakanishi 2014).

Are there common features of the reported studies that could be integrated into a microglial endophenotype that increases the risk for neurodegeneration in adulthood? Perhaps an immunosenescence perspective can help shed light on possible mechanisms of early-life programming of neurodegeneration (Fulop, Larbi et al. 2017). What distinguishes the centenarians that remain untouched from neurodegenerative conditions? The common denominator appears to be their subjective innate or acquired resilience (Krohne 2001, Franceschi and Bonafe 2003, Southwick S 2012). Is the subjective processing of uncertainty as "less or not stressful" a key to long life with reduced immunosenescence and hence delayed or no neurodegeneration (Peters, McEwen et al. 2017)?

Peters et al. propose that there is a cerebral metabolic cost to processing uncertainty in information, a hallmark of chronic stress (Peters, McEwen et al. 2017). Early life inflammatory exposures reprogram fetal microglia toward a distinct immunometabolic phenotype defined by what teleologically appears to be energy preservation (Cao, Cortes et al. 2015). Taken together, does this implies that stress/uncertainty-imposed energy demands of information processing cannot be met fully by a stressed brain? Indeed, microglial senescence is discussed as a contributor to age-related neurodegeneration (Luo, Ding et al. 2010, von Bernhardt, Eugenin-von Bernhardt et al. 2015). Little is known about the control mechanisms governing the metabolic changes within the microglia which occur to meet the requirements of their phenotypic switch (Borst, Schwabenland et al. 2018). Similar to our findings in ovine fetal microglia in response to inflammation, metabolic changes do correlate with the ability of innate immune cells to show hallmarks of adaptive immune responses (Borst, Schwabenland et al. 2018).

Is this immunometabolic endophenotype inherited multigenerationally via the DoHAD pathway of immunosenescence (Hanson, Cooper et al. 2016)? Fetal microglia and astrocytes exhibit memory of preceding insults (Cao, Cortes et al. 2015, Frasch 2018, Cao, MacDonald et al. 2019). Does such plasticity and memory of experienced insults come at a cost of a reduced energy reserve for future hits? Does such reduced reserve translate into an increased susceptibility to adult neurodegenerative diseases (Paolicelli, Bolasco et al. 2011)?

In summary, increasing support for mechanisms representing microglial memory emerge, as well as new questions as to whether these new players in the etiology of neurodegenerative diseases also lend themselves as novel therapeutic targets which modulate the microglial memory by interfering with its programming.

5. Role of Microglia in Adult Neurodegenerative disorders: early life origins

Inflammation is a prominent axis of neuropathology common to most neurodegenerative disorders in adulthood. Stress has also been coming increasingly into focus as an important contributor, perhaps even as a trigger of clinical manifestation. The involvement of exacerbated microglia and astroglia reactivity in the pathophysiology of neurodegeneration is indisputable, but their precise roles and patterns of interaction with triggers such as inflammation or stress remain subject of ongoing research.

Alzheimer's disease, neuroinflammation and stress

AD is a multifactorial neurodegenerative disorder that affects nearly 50 million people worldwide, representing the most prevalent form of dementia in older adults. AD is manifested clinically by progressive memory loss and a gradual decline in global cognitive function that interferes with daily living. At the neuropathological level, AD is characterized by accumulation of amyloid- β (A β) in amyloid plaques, phosphorylated Tau protein in neurofibrillary tangles, and progressive neuronal loss in the neocortex and the hippocampus (Querfurth and LaFerla 2010).

Inflammation is a major feature of AD pathology (Gorelick 2010). Cytokines, chemokines and complement factors are found in the cerebrospinal fluid (CSF) and amyloid plaques in the brain of AD patients. Several epidemiological studies and clinical trials link inflammatory markers to dementia and cognitive impairment (Beard, Waring et al. 1998, Aisen, Schafer et al. 2003, Barber 2011). Moreover, the expression of inflammation-related genes varies as disease progresses, suggesting their role in pathophysiology (Bossers, Wirz et al. 2010).

Ageing and neurodegeneration diminish microglial function, as evidenced by disruption of microglia-specific transcripts such as TREM2 and CD33 in AD brains (Clayton, Van Enoo et al. 2017). Interaction of microglia with A β plaques activates the pro-phagocytic phenotype (M2) to clear the aggregates. However, as the plaque burden increases in the brain overtime, microglia shift towards a pro-inflammatory phenotype (M1), triggering chronic inflammation and neuronal death (Tang and Le 2016). A β -stimulated microglia show high levels of phagocytic markers such as *AXL*, *CLEC7A*, *LGALS3*, *CD11C*, *TREM2*, and

TYROBP. While this activation may be beneficial for the clearance of protein aggregates, a hyperactive response to A β has been reported in the brains of early onset AD cases and may be associated with neuronal death (Yin, Raj et al. 2017).

While amyloid plaques are formed by the assemblage of large insoluble fibrils, smaller soluble A β oligomers can spread in the brain and are the most toxic forms that induce synaptic dysfunction (Smith and Strittmatter 2017). Interaction of these oligomers with TLR2 receptors in microglia induces a neurotoxic response with increased transcription of pro-inflammatory molecules like iNOS and TNF α (Heurtaux, Michelucci et al. 2010, Liu, Liu et al. 2012). Furthermore, A β oligomers persistently activate the tyrosine kinase pathway sustaining the release of neurotoxic factors (Dhawan, Floden et al. 2012) and the upregulation of TNF α and cytokines IL-1 and IL-6 (Meda, Cassatella et al. 1995).

Remarkably, studies in genetic mouse models of AD and indirect results in non-human primates indicate that chronic stress increases A β -mediated neuronal toxicity or increases Tau accumulation or phosphorylation and tangle formation (Dong and Csernansky 2009). A sustained neuroinflammation was suggested as a link between the initial A β pathology and the later tangle formation (Kinney, Bemiller et al. 2018). Future animal studies need to examine whether removing the microglial memory of prenatal insults via PS or infection may halt or at least slow down the progression of the three core AD features, A β , tangles and the chronic inflammation and, ultimately, the behavioral dementia phenotype.

Parkinson's disease, neuroinflammation and stress

PD is the second most frequent neurodegenerative disorder of the elderly, characterized clinically by motor impairment, gait disturbance, tremor and increased risk to dementia. At the neuropathological level, PD brains present with an accumulation of α -synuclein (α -syn) aggregates in Lewy body structures, mainly in the substantia nigra (SN) and loss of dopaminergic neurons (Spillantini, Schmidt et al. 1997, Takeda, Mallory et al. 1998, Burn 2006). PD is a multifactorial disorder where genetic and environmental factors converge to generate pathology, and more than 90% of cases are of sporadic origin. Emerging data supports that chronic neuroinflammation is highly prevalent in PD, and increased number of microglia and microgliosis have been reported in postmortem PD brains and transgenic animal models of PD (Watson, Richter et al. 2012, Doorn, Moors et al. 2014). Importantly, microgliosis is more evident in the vicinity of dopaminergic neurons primed for degeneration in the SN, hippocampus and cortex (McGeer, Itagaki et al. 1988, Banati, Daniel et al. 1998, Imamura, Hishikawa et al. 2003, Sawada, Imamura et al. 2006). Activated microglia produce high levels of pro-inflammatory molecules like TNF α , IL6, nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) that contribute to the cell-specific vulnerability in PD (Hunot, Boissiere et al. 1996, Knott, Stern et al. 2000, Block, Zecca et al. 2007, Dufek, Rektorova et al. 2015). Indeed, a higher density of activated microglia was observed in nigral neurons of mice exposed to the pro-inflammatory bacterial LPS. This region-specific response may render the SN more vulnerable to neuronal death than cells in the cortex or hippocampus correlating with the disease pathology (Kim, Mohney et al. 2000).

Exacerbated neuronal death, on the other hand, can also trigger microglial activation thus feeding a deleterious loop. Substances which are produced by dying dopaminergic neurons that can activate microglia include α -syn aggregates, ATP, matrix metalloproteinase-3 (MMP-3) and neuromelanin (Wilms, Rosenstiel et al. 2003, Davalos, Grutzendler et al. 2005, Zhang, Wang et al. 2005, Kim, Choi et al. 2007). Notably, suppression of microglial activation alleviates the PD phenotype in mouse models, further supporting the role of these cells in the pathophysiology (Wu, Jackson-Lewis et al. 2002).

Last but not least, chronic stress, including ELS, has been reported to contribute to PD etiology, potentially triggering PD (Hemmerle, Herman et al. 2012, Djamshidian and Lees 2014, Dalle and Mabandla 2018).

Innate immune system, ELS, inflammation and neurodegeneration in adult life

The role of the innate immune system in AD has gained attention after several genome-wide association studies identified disease-associated genomic risk loci that map to immune response genes and genes expressed by microglia. A recent study identified 29 risk loci associated to 215 genes with potential of causing AD; many of them were highly expressed in immune-related cells, including microglia (Jansen, Savage et al. 2019). Among these, *INPP5D*; *GPSM3*; *PILRA*; *MS4A6A*; *MS4A7*; *RIN3* and *HMHA1* are microglia-enriched genes expressed in brain regions relevant to AD and associated with Braak staging and as measure of disease progression (Kunkle, Grenier-Boley et al. 2019). Interestingly, two studies identified a single-nucleotide polymorphism (SNP) at the third intron in *KAT8* as a new AD risk locus. Multiple variants in this locus influence *KAT8* expression and methylation levels, thus also linking epigenetic changes to AD risk (Marioni, Harris et al. 2018, Jansen, Savage et al. 2019).

While evidence supports the role of neuroinflammation in disease causation, the mechanisms that trigger this process and how inflammation reaches the brain are still not fully understood. One plausible explanation is that AD involves systemic alterations rather than being restricted to the brain. The innate immune response system eliminates pathogens in a fast and non-specific reaction involving inflammation. In the periphery, this system is composed by neutrophils, monocytes/macrophages, dendritic cells and natural killer cells, while in the brain this function is fulfilled by the resident microglia (Guillot-Sestier, Doty et al. 2015, Crotti and Ransohoff 2016, Le Page, Dupuis et al. 2018). Adaptive immunity, however, cannot be initiated directly in the brain. Once microglia are activated in response to an insult, secretion of cytokines and chemokines is increased, attracting circulating lymphoid and myeloid cells and thus establishing a communication between the brain and the systemic immune response mechanisms (Ransohoff and Brown 2012). In addition, alterations in the brain blood barrier observed in most neurodegenerative diseases, facilitate the flow of inflammation-related molecules between the brain and the systemic circulation, enabling the cross-talk between these systems (Busse, Michler et al. 2017). Therefore, adverse events during early life may affect the communication between brain and periphery paving the road for inflammatory-initiated diseases during adulthood.

Prenatal challenging of the immune system by exposure of mice to Poly I:C (polyriboinosinic–polyribocytidilic acid) during gestation as a model of viral infections,

results in chronic elevation of inflammatory cytokines, higher levels of amyloid precursor protein (APP) in the hippocampus, increased Tau phosphorylation and defective working memory in old age animals - features directly associated with AD pathology. These alterations are accompanied by microglial activation and reactive gliosis suggesting that priming the microglial system during early life favors a chronic inflammatory state that seeds neurodegenerative changes in the adult (Krstic, Madhusudan et al. 2012). As emerging evidence links viral infections with AD pathology (Readhead, Haure-Mirande et al. 2018), a provocative question is whether early-life exposure to viruses may contribute to this increased risk for AD.

Multiple environmental toxins, particularly agrichemicals, have been linked to increased risk for PD (Wang, Costello et al. 2011, Desplats, Patel et al. 2012) and in many cases inflammation seems to be the underlying mechanism. Emerging evidence suggests that infections during the prenatal life also impact PD susceptibility (Collins, Toulouse et al. 2012). Maternal infections like bacterial vaginosis may increase the risk of the neonate to develop PD, an effect apparently mediated by the rise in chorioamniotic LPS and TNF- α levels in infected pregnant women, that hinders the development of dopaminergic neurons (Okada, Matsuzaki et al. 1997, Ling, Gayle et al. 2002).

Similarly, prenatal exposure to LPS increases the vulnerability of rats to rotenone in later life, resulting in synergistic effects that increase loss of tyrosine-hydroxylase (TH) cells in the SN in comparison to LPS-naïve animals. Dopaminergic cell loss was associated with increased levels of TNF- α and reactive microglia (Ling, Chang et al. 2004). Other studies also support the idea that viral infections in the prenatal environment can prime the organism to develop PD as adults, potentially due to changes in density and/or activation states of microglia. *In utero* exposure to the synthetic dsRNA analogue Poly I:C increases the production of pro-inflammatory cytokines in the brain of exposed rats (Cunningham, Campion et al. 2007). Importantly, these events aggravate neurodegeneration inducing severe decay of the nigrostriatal dopaminergic system in adult animals (Deleidi, Hallett et al. 2010, Field, Campion et al. 2010). While the specific role of microglia in mediating prenatal infections, dopaminergic neuronal loss and PD risk is yet to be defined, taken together, these studies point at inflammation as an important agent contributing to PD risk via a modulation of the microglial phenotype.

6. Epigenetic mechanisms link prenatal adverse environment, microglial memory and activation with adult neurodegenerative disorders

Epigenetic mechanisms that dictate chromatin accessibility, such as DNA methylation and post-transcriptional histone modifications, modulate gene expression and are dynamically regulated in post-mitotic neurons. As these mechanisms have crucial functions in memory formation and synaptic plasticity (Day and Sweatt 2010, Sen 2015, Cholewa-Waclaw, Bird et al. 2016), it is not surprising that alterations in epigenetic regulation play a role in neurodegeneration. For example, AD brains show a general decay in global methylation and acceleration of aging as measured by methylation markers, particularly in areas selectively vulnerable to pathology (Urduingio, Sanchez-Mut et al. 2009, Mastroeni, Grover et al. 2010,

Levine, Lu et al. 2015). In PD brains, we observed aberrant cytoplasmic localization of DNA methyl transferase 1 (DNMT1) in neurons due to interaction with aggregated α -syn resulting in reduced global methylation, including genes associated with PD pathology (Desplats, Spencer et al. 2011).

Epigenetic modulation of microglial memory due to inflammation

Notably, epigenome-wide association studies in cognitively impaired subjects and AD cases identified significant changes in DNA methylation at 71 methylation sites across the genome, that correlated with AD pathology burden. Among the differentially methylated genes were *ANK1* and *RHBDF2* which are involved in the signaling cascade that modulates the activation of microglia and the infiltrating macrophages to release TNF α from the cell surface (De Jager, Srivastava et al. 2014). More recently, *ANK1* was reported to be specifically upregulated in microglia isolated from the hippocampus of AD brains, without significant changes detected in neurons or astrocytes from the same samples (Mastroeni, Sekar et al. 2018). Therefore, methylation changes associated with AD pathology appear to regulate the activation of microglia and to play important roles in neuroinflammation.

Interestingly, work using inducible AD mouse models showed that early stages of pathology are associated with dynamic changes in chromatin structure nearby immune response genes. These changes include increased accessibility for the ETS family of transcriptional regulators, like PU.1, which are implicated in activation of macrophages. When mapped to orthologous regions in the human genome, the enhancers activated in the mice hippocampus corresponded to immune cell expression quantitative trait loci, further implicating immune processes in AD predisposition, and the involvement of chromatin remodeling in triggering inflammatory responses (Gjoneska, Pfenning et al. 2015).

As mentioned before, another microglial factor, TREM2, has gained attention in AD research following the identification of genetic variants in this gene associated with increased disease risk (Jin, Benitez et al. 2014). TREM2 is expressed by activated microglia and presents with differential DNA methylation in AD brains (Smith, Smith et al. 2016) supporting a role for the epigenetic machinery in the modulation of the microglial transcriptome that may cause neurodegeneration.

Key genes at almost every level of the inflammation response appear to be regulated by DNA methylation, including IL-2, CXCL2 and chemokine receptors CXCR4 and CCR7 (Bruniquel and Schwartz 2003, Mori, Kim et al. 2005, Murayama, Sakura et al. 2006, Ramos, Grochoski et al. 2011, Fischer, Onur et al. 2012). Moreover, the regulation of IL-6 requires the cross-talk between different epigenetic players including TET2 to regulate DNA methylation and HDAC2 to modulate histone acetylation, a process that reduces inflammation by repression of IL-6 in macrophages (Zhang, Zhao et al. 2015).

Microglia activation may also be dependent on histone modifications. Suh *et al.* showed that treatment with histone deacetylase inhibitors (HDACi) decreases the release of cytokines, including TNF α , IL-10, IL-1 α and IL-6 suggesting that histone modifications may repress the microglial immune responses (Suh, Choi et al. 2010). More recently, using a mouse model where knock down of *Hdac1* and *Hdac2* was specifically directed to microglia, Datta

et al. demonstrated that while these enzymes are not required for the survival of adult microglia in the normal brain, the deletion of Hdac1 and Hdac2 in the context of AD pathology increases the phagocytic activity of microglia, reducing amyloid plaques and cognitive decline (Datta, Staszewski et al. 2018).

Datta et al. also investigated the effects of prenatal ablation of HDACs, taking advantage of their inducible model. Interestingly, the lack of these histone-modifying enzymes early in life alters microglial proliferation and increases apoptosis, likely due to activation of cell death-signaling pathways at the transcriptional level (Datta, Staszewski et al. 2018). In a similar context, prenatal exposure to HDACi valproic acid results in higher density of microglia as well as modification of histones, further suggesting that modulation of histone changes directly affects microglia abundance (Kazlauskas, Campolongo et al. 2016). This epigenetic cascade seems to propagate across CNS cell types: activated microglia induce histone deacetylation in astrocytes reducing glutathione (GSH) transcription (Correa, Mallard et al. 2011). Low levels of GSH, in turn, trigger inflammatory molecules such as TNF- α , IL-6 and also stimulate kinase pathways further exacerbating the inflammatory state in neurodegenerative disorders (Lee, Cho et al. 2010, Pocernich and Butterfield 2012).

A more recent study supports the notion that immune memory in macrophages is executed by epigenetic alterations. Changes in histone methylation (H3K4me1) and acetylation (H3K27ac) associate with activation of enhancers that modulate inflammation-related genes. Notably, this study demonstrated that peripheral inflammation induces epigenetic remodeling in brain-resident microglia which then become tolerant to further inflammatory stimuli for at least 6-months, a phenomenon that alleviates amyloidosis in a mouse model of AD (Wendeln, Degenhardt et al. 2018). These results support the role of ELS-induced microglial memory in shaping the trajectory of AD pathology in later life.

Epigenetic modulation of microglial memory due to psychological and nutritional stress

Epigenetic mechanisms also mediate the effects of maternal behavior modulating microglial responses in the offspring's brain. Increased maternal care stimulates the expression of IL-10 in newborn rats in a model of drug addiction. The effect, mediated by a reduction in IL-10-promoter methylation, appears to be specific to microglia. Elevated IL-10 is sustained throughout adulthood in the Nucleus accumbens and reduces microglial reactivity after drug exposure preventing reinstatement of morphine addiction in adult animals (Schwarz, Hutchinson et al. 2011). While this study was focused on a different paradigm, it provides another example on how epigenetic remodeling is a likely mediator of early life experience that can modulate microglial responses and disease risk in later life. Future studies in animal models and human cohorts may identify epigenetic biomarkers of ELS that predict increased risk to neurodegenerative diseases in adult life.

Chronic stress may impact negatively the dietary choices (Yau and Potenza 2013), so the impact of diet on neurodegeneration is important to consider in the present context. Diet also has crucial roles in shaping the early life environment, and the consequences of malnutrition or dietary deficiency may be long-lasting. For example, maternal immune activation due to exposure to inflammatory stimuli induces persistent changes in the fatty acid composition of the fetal brain. These alterations in neurodevelopment are associated with a reduction in the

levels of n-3 polyunsaturated fatty acids (e.g., omega-3) in the offspring that are manifested later in life as memory and behavioral impairments (Labrousse, Leyrolle et al. 2018, Yam, Schipper et al. 2019).

Similarly, zinc deprivation associated with malnutrition, ageing or disease induces the production of pro-inflammatory cytokines IL-1 β and TNF- α involving both, redox-dependent mechanisms and chromatin rearrangements (Wessels, Haase et al. 2013). Still, more research is needed to determine whether zinc deficiency during early life is another factor that primes microglia for hyperactivation in later life.

Homocysteine (Hcy) is another metabolite regulated by diet and associated with neurodegeneration. Hcy is a byproduct of the one-carbon metabolism pathway which produces the methyl groups incorporated into DNA or proteins by conversion of SAM (S-adenosyl methionine) into SAH (S-adenosyl homocysteine). High levels of Hcy inhibit DNA-methyl transferase enzymes affecting the epigenome and the transcriptome and also impacting the responses to oxidation and inflammation (Ducker and Rabinowitz 2017). Increased Hcy levels have been associated with AD and PD progression (Christine, Auinger et al. 2018, Baroni, Bonetto et al. 2019) and importantly, can influence the transition from cognitive impairment into dementia (Reitz, Tang et al. 2009, Blasko, Hinterberger et al. 2012). Since the levels of Hcy in healthy subjects are primarily determined by dietary intake of methionine, folate and vitamin B12; early life nutritional stress may prime the organism for neurological disease (Moretti and Caruso 2019). Hcy induces proliferation and activation of microglia in vitro and increases oxidative stress and microgliosis in rodent models (Zou, Zhao et al. 2010). Furthermore, Li et al. showed that hyperhomocysteinemia induced in mice by supplementation with methionine, increases the level of inflammation markers TNF α and IL-1 β in plasma, along with changes in the expression of cystathionine γ -lyase (CSE) in macrophages. Importantly, in vitro testing showed that these alterations were mediated by epigenetic changes - namely increased DNA methylation at CSE promoter - and may serve as a form of macrophage memory (Li, Li et al. 2015). Hcy was implicated in chronic stress-induced A β protein accumulation due to APP misprocessing and with cognitive decline in adult rats further supporting the role of Hcy in AD via solely dietary or stress-triggered signaling cascades (Xie, Zhao et al. 2016). More research is needed to understand the potential impact of imbalanced micronutrient intake and its interplay with stress exposures during early life on Hcy metabolism and whether this early insult will sustain long-lasting deleterious effects in the brain via microglial priming.

7. Can early-life programming of microglia be reversed? Looking for new therapeutic targets

While an adverse prenatal environment seems to increase the risk for neurodegeneration in later life, exposure to an enriched environment (EE) during early life may reduce the odds of neurodegeneration. Furthermore, this mechanism is mediated by microglia. EE is known to induce neurogenesis (Clemenson, Lee et al. 2015), and some studies suggest that EE can impact the number of microglia in cortex and hippocampus, also affecting their inflammatory and phagocytic activity (Williamson, Chao et al. 2012). A recent study showed

that EE can modulate microglia in the dentate gyrus reducing the inflammatory response of microglia after exposure to A β oligomers (Xu, Gelyana et al. 2016). Not surprisingly, EE-associated behavior reduces chronic stress, a pathway we invoked repeatedly in this review as the likely common culprit of multi-hit etiology which manifests a disease susceptibility into a clinical neurodegenerative phenotype.

Early life malnutrition may have a deleterious impact on the brain by increasing inflammation, but its mechanism of action also opens another opportunity for intervention. Manipulation of dietary intake of folate and omega-3 seems to reduce the effects of ELS on memory and cognition. For instance, manipulation of the ratios of long-chain polyunsaturated fatty acids in the dietary intake serves to increase the availability of omega-3 and has protective effects against ELS-associated cognitive impairment via modulation of microglia in the hippocampus (Yam, Schipper et al. 2019).

Importantly, international consensus was recently reached in declaring elevated plasma levels of Hcy as a modifiable risk factor for dementia in the elderly. This factor has a population attributable risk that ranges from 4.1% to 30% and can be safely treated by supplementation with vitamin B (Smith, Refsum et al. 2018). Moreover, a recent study by Velazquez et al. reported beneficial effects of maternal choline supplementation in reducing Hcy levels in the offspring. Hcy reduction was associated with amelioration of AD pathology in transgenic mice models, including reduction of A β aggregates and microgliosis and improvement in cognitive function. The most remarkable finding of this study is that the benefits of diet manipulation extended across generations, and animals that were never exposed to choline supplementation but were born from the offspring of treated parents, still benefited from the intervention and showed a milder AD phenotype (Velazquez, Ferreira et al. 2019). Taking in all, these results suggest that early life dietary interventions may potentially revert adverse environmental cues, a mechanism that may be associated with microglial memory and epigenetic remodeling.

Pioneering work by Ben Barres and Beth Stevens labs highlighted the role of the complement pathway in the microglial-neuronal interactions which make the brain more vulnerable to AD over time (Schafer, Lehrman et al. 2012, Hong, Beja-Glasser et al. 2016). Similar signaling pathways, particularly the iron homeostasis pathway, mediate microglial memory of many different *in utero* insults; even when the adverse event is clinically asymptomatic (Cortes, Cao et al. 2017). Hyperactive microglia may prevent synaptogenesis thus predisposing to AD in later life (Stephan, Barres et al. 2012, Hong, Beja-Glasser et al. 2016). In primary fetal ovine microglia cultures, agonistic stimulation of the α 7nACh receptor up-regulated C3AR1 (Cortes, Cao et al. 2017). These findings warrant further investigation as pro-cholinergic drugs are used in the treatment of AD symptoms although the consequences of cholinergic stimulation on microglial signaling are not yet well understood. Will selective blocking rather than enhancing α 7nAChR signaling in microglia be potentially more beneficial for mitigating the AD progression by reducing the pace of synaptic degradation?

8. Conclusions

We provide evidence supporting the role of early life programming in the susceptibility for adult neurodegenerative diseases while highlighting questions and proposing avenues for future research to advance our understanding of this fundamental process. The key elements of this phenomenon are chronic stress, neuroinflammation triggering microglial polarization, microglial memory and their connection to neurodegeneration.

While this review focused on microglia, a full understanding of brain programming predisposing to neurodegenerative diseases will require incorporation of astrocytes and oligodendroglia and their dynamic interactions with microglia and neuronal cells (Hong, Beja-Glasser et al. 2016, Liddelow, Guttenplan et al. 2017, Dutta, Woo et al. 2018).

We synthesize the reviewed mechanisms in Figure 1 which integrates the compounded impact of PS as well as the accompanying and independently occurring systemic and neuroinflammation on the glial energy reserves. The evolving metabolic phenotype of the stressed brain may represent the bottleneck substrate of the emergent, inherited and acquired resilience phenotype which, in turn, over multiple, subclinical hits with PS and/or inflammation modulates the progression of immunosenescence and the risk for neurodegeneration. Such framework offers a number of opportunities for early therapeutic interventions with long-term health benefits reducing the risk for neurodegeneration by modulating microglial immunometabolism.

ACKNOWLEDGEMENTS

This work was partially supported by grants NS092803 and NS104013 from NINDS to P.D. MGF is funded by Canadian Institutes of Health Research (CIHR). MCA is funded, in part, by Hans Fisher Senior Fellowship (Institute for Advanced Study-Technical University Munich (IAS-TUM), Munich, Germany).

REFERENCES

- Adrover E, Pallares ME, Baier CJ, Monteleone MC, Giuliani FA, Waagepetersen HS, Brocco MA, Cabrera R, Sonnewald U, Schousboe A and Antonelli MC (2015). "Glutamate neurotransmission is affected in prenatally stressed offspring." *Neurochem Int* 88: 73–87. [PubMed: 26026592]
- Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ and Alzheimer's Disease Cooperative S (2003). "Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial." *JAMA* 289(21): 2819–2826. [PubMed: 12783912]
- Andersen SL (2003). "Trajectories of brain development: point of vulnerability or window of opportunity?" *Neurosci Biobehav Rev* 27(1–2): 3–18. [PubMed: 12732219]
- Baier CJ, Pallares ME, Adrover E, Katunar MR, Raisman-Vozari R and Antonelli MC (2014). "Intrastratial 6-OHDA lesion differentially affects dopaminergic neurons in the ventral tegmental area of prenatally stressed rats." *Neurotox Res* 26(3): 274–284. [PubMed: 24934701]
- Baier CJ, Pallares ME, Adrover E, Monteleone MC, Brocco MA, Barrantes FJ and Antonelli MC (2015). "Prenatal restraint stress decreases the expression of alpha-7 nicotinic receptor in the brain of adult rat offspring." *Stress* 18(4): 435–445. [PubMed: 25798813]
- Banati RB, Daniel SE and Blunt SB (1998). "Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease." *Mov Disord* 13(2): 221–227. [PubMed: 9539333]
- Barber R (2011). "Inflammatory signaling in Alzheimer disease and depression." *Cleve Clin J Med* 78 Suppl 1: S47–49. [PubMed: 21972331]

- Barker DJ (1993). "Fetal origins of coronary heart disease." *Br Heart J* 69(3): 195–196. [PubMed: 8461215]
- Baroni L, Bonetto C, Rizzo G, Bertola C, Caberlotto L and Bazzlerla G (2019). "Association Between Cognitive Impairment and Vitamin B12, Folate, and Homocysteine Status in Elderly Adults: A Retrospective Study." *J Alzheimers Dis*.
- Barros VG, Duhalde-Vega M, Caltana L, Brusco A and Antonelli MC (2006). "Astrocyte-neuron vulnerability to prenatal stress in the adult rat brain." *J Neurosci Res* 83(5): 787–800. [PubMed: 16493669]
- Beard CM, Waring SC, O'Brien PC, Kurland LT and Kokmen E (1998). "Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984." *Mayo Clin Proc* 73(10): 951–955. [PubMed: 9787743]
- Ben-Ari Y (2008). "Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders." *Trends Neurosci* 31(12): 626–636. [PubMed: 18951639]
- Berger MA, Barros VG, Sarchi MI, Tarazi FI and Antonelli MC (2002). "Long-term effects of prenatal stress on dopamine and glutamate receptors in adult rat brain." *Neurochem Res* 27(11): 1525–1533. [PubMed: 12512957]
- Bilbo S and Stevens B (2017). "Microglia: The Brain's First Responders." *Cerebrum* 2017.
- Blasko I, Hinterberger M, Kemmler G, Jungwirth S, Krampla W, Leitha T, Tragl K, Heinz P and Fischer P (2012). "Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort." *J Nutr Health Aging* 16(8): 687–694. [PubMed: 23076510]
- Block ML, Zecca L and Hong JS (2007). "Microglia-mediated neurotoxicity: uncovering the molecular mechanisms." *Nat Rev Neurosci* 8(1): 57–69. [PubMed: 17180163]
- Bock J, Wainstock T, Braun K and Segal M (2015). "Stress In Utero: Prenatal Programming of Brain Plasticity and Cognition." *Biol Psychiatry* 78(5): 315–326. [PubMed: 25863359]
- Borst K, Schwabenland M and Prinz M (2018). "Microglia metabolism in health and disease." *Neurochem Int*: 104331. [PubMed: 30423423]
- Bossers K, Wirz KT, Meerhoff GF, Essing AH, van Dongen JW, Houba P, Kruse CG, Verhaagen J and Swaab DF (2010). "Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease." *Brain* 133(Pt 12): 3699–3723. [PubMed: 20889584]
- Bruniquel D and Schwartz RH (2003). "Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process." *Nat Immunol* 4(3): 235–240. [PubMed: 12548284]
- Brunson KL, Kramar E, Lin B, Chen Y, Colgin LL, Yanagihara TK, Lynch G and Baram TZ (2005). "Mechanisms of late-onset cognitive decline after early-life stress." *J Neurosci* 25(41): 9328–9338. [PubMed: 16221841]
- Burn DJ (2006). "Cortical Lewy body disease and Parkinson's disease dementia." *Curr Opin Neurol* 19(6): 572–579. [PubMed: 17102696]
- Busse M, Michler E, von Hoff F, Dobrowolny H, Hartig R, Frodl T and Busse S (2017). "Alterations in the Peripheral Immune System in Dementia." *J Alzheimers Dis* 58(4): 1303–1313. [PubMed: 28582858]
- Cao M, Cortes M, Moore CS, Leong SY, Durosier LD, Burns P, Fecteau G, Desrochers A, Auer RN, Barreiro LB, Antel JP and Frasch MG (2015). "Fetal microglial phenotype in vitro carries memory of prior in vivo exposure to inflammation." *Front Cell Neurosci* 9: 294. [PubMed: 26300730]
- Cao M, MacDonald JW, Liu HL, Weaver M, Cortes M, Durosier LD, Burns P, Fecteau G, Desrochers A, Schulkin J, Antonelli MC, Bernier RA, Dorschner M, Bammler TK and Frasch MG (2019). "alpha7 Nicotinic Acetylcholine Receptor Signaling Modulates Ovine Fetal Brain Astrocytes Transcriptome in Response to Endotoxin." *Front Immunol* 10: 1063. [PubMed: 31143190]
- Cholewa-Waclaw J, Bird A, von Schimmelmann M, Schaefer A, Yu H, Song H, Madabhushi R and Tsai LH (2016). "The Role of Epigenetic Mechanisms in the Regulation of Gene Expression in the Nervous System." *J Neurosci* 36(45): 11427–11434. [PubMed: 27911745]
- Christine CW, Auinger P, Joslin A, Yelapaala Y, Green R and D. I. Parkinson Study Group (2018). "Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease." *Mov Disord* 33(5): 762–770. [PubMed: 29508904]
- Clayton KA, Van Enoo AA and Ikezu T (2017). "Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy." *Front Neurosci* 11: 680. [PubMed: 29311768]

- Clemenson GD, Lee SW, Deng W, Barrera VR, Iwamoto KS, Fanselow MS and Gage FH (2015). "Enrichment rescues contextual discrimination deficit associated with immediate shock." *Hippocampus* 25(3): 385–392. [PubMed: 25330953]
- Collins LM, Toulouse A, Connor TJ and Nolan YM (2012). "Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease." *Neuropharmacology* 62(7): 2154–2168. [PubMed: 22361232]
- Conradt E, Adkins DE, Crowell SE, Raby KL, Diamond LM and Ellis B (2018). "Incorporating epigenetic mechanisms to advance fetal programming theories." *Dev Psychopathol* 30(3): 807–824. [PubMed: 30068415]
- Correa F, Mallard C, Nilsson M and Sandberg M (2011). "Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3beta." *Neurobiol Dis* 44(1): 142–151. [PubMed: 21757005]
- Cortes M, Cao M, Liu HL, Moore CS, Durosier LD, Burns P, Fecteau G, Desrochers A, Barreiro LB, Antel JP and Frasch MG (2017). "alpha7 nicotinic acetylcholine receptor signaling modulates the inflammatory phenotype of fetal brain microglia: first evidence of interference by iron homeostasis." *Sci Rep* 7(1): 10645. [PubMed: 28878260]
- Crotti A and Ransohoff RM (2016). "Microglial Physiology and Pathophysiology: Insights from Genome-wide Transcriptional Profiling." *Immunity* 44(3): 505–515. [PubMed: 26982357]
- Cunningham C, Champion S, Teeling J, Felton L and Perry VH (2007). "The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C)." *Brain Behav Immun* 21(4): 490–502. [PubMed: 17321719]
- Dalle E and Mabandla MV (2018). "Early Life Stress, Depression And Parkinson's Disease: A New Approach." *Mol Brain* 11(1): 18. [PubMed: 29551090]
- Datta M, Staszewski O, Raschi E, Frosch M, Hagemeyer N, Tay TL, Blank T, Kreutzfeldt M, Merkler D, Ziegler-Walckirch S, Matthias P, Meyer-Luehmann M and Prinz M (2018). "Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner." *Immunity* 48(3): 514–+. [PubMed: 29548672]
- Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML and Gan WB (2005). "ATP mediates rapid microglial response to local brain injury in vivo." *Nat Neurosci* 8(6): 752–758. [PubMed: 15895084]
- Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C and Berk M (2016). "A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis." *Neurosci Biobehav Rev* 65: 185–194. [PubMed: 27073049]
- Day JJ and Sweatt JD (2010). "DNA methylation and memory formation." *Nat Neurosci* 13(11): 1319–1323. [PubMed: 20975755]
- De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, Eaton ML, Keenan BT, Ernst J, McCabe C, Tang A, Raj T, Replogle J, Brodeur W, Gabriel S, Chai HS, Younkin C, Younkin SG, Zou F, Szyf M, Epstein CB, Schneider JA, Bernstein BE, Meissner A, Ertekin-Taner N, Chibnik LB, Kellis M, Mill J and Bennett DA (2014). "Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci." *Nat Neurosci* 17(9): 1156–1163. [PubMed: 25129075]
- Deleidi M, Hallett PJ, Koprach JB, Chung CY and Isacson O (2010). "The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration." *J Neurosci* 30(48): 16091–16101. [PubMed: 21123556]
- Desplats P, Patel P, Kosberg K, Mante M, Patrick C, Rockenstein E, Fujita M, Hashimoto M and Masliah E (2012). "Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease." *Mol Neurodegener* 7: 49. [PubMed: 23017109]
- Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, Adame A, Rockenstein E and Masliah E (2011). "Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases." *J Biol Chem* 286(11): 9031–9037. [PubMed: 21296890]

- Dhawan G, Floden AM and Combs CK (2012). "Amyloid-beta oligomers stimulate microglia through a tyrosine kinase dependent mechanism." *Neurobiol Aging* 33(10): 2247–2261. [PubMed: 22133278]
- Diz-Chaves Y, Pernia O, Carrero P and Garcia-Segura LM (2012). "Prenatal stress causes alterations in the morphology of microglia and the inflammatory response of the hippocampus of adult female mice." *J Neuroinflammation* 9: 71. [PubMed: 22520439]
- Djamshidian A and Lees AJ (2014). "Can stress trigger Parkinson's disease?" *J Neurol Neurosurg Psychiatry* 85(8): 878–881. [PubMed: 24259593]
- Dong H and Csernansky JG (2009). "Effects of stress and stress hormones on amyloid-beta protein and plaque deposition." *J Alzheimers Dis* 18(2): 459–469. [PubMed: 19584430]
- Doom KJ, Moors T, Drukarch B, van de Berg W, Lucassen PJ and van Dam AM (2014). "Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients." *Acta Neuropathol Commun* 2: 90. [PubMed: 25099483]
- Ducker GS and Rabinowitz JD (2017). "One-Carbon Metabolism in Health and Disease." *Cell Metab* 25(1): 27–42. [PubMed: 27641100]
- Dufek M, Rektorova I, Thon V, Lokaj J and Rektor I (2015). "Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study." *Parkinsons Dis* 2015: 898192. [PubMed: 26351617]
- Dutta DJ, Woo DH, Lee PR, Pajevic S, Bukalo O, Huffman WC, Wake H, Basser PJ, SheikhBahaei S, Lazarevic V, Smith JC and Fields RD (2018). "Regulation of myelin structure and conduction velocity by perinatal astrocytes." *Proc Natl Acad Sci U S A* 115(46): 11832–11837. [PubMed: 30373833]
- Faa G, Marcialis MA, Ravarino A, Piras M, Pintus MC and Fanos V (2014). "Fetal programming of the human brain: is there a link with insurgence of neurodegenerative disorders in adulthood?" *Curr Med Chem* 21(33): 3854–3876. [PubMed: 24934353]
- Fanni D, Gerosa C, Rais M, Ravarino A, Van Eyken P, Fanos V and Faa G (2018). "The role of neuropathological markers in the interpretation of neuropsychiatric disorders: Focus on fetal and perinatal programming." *Neurosci Lett* 669: 75–82. [PubMed: 27818357]
- Field R, Campion S, Warren C, Murray C and Cunningham C (2010). "Systemic challenge with the TLR3 agonist poly I:C induces amplified IFN α /beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration." *Brain Behav Immun* 24(6): 996–1007. [PubMed: 20399848]
- Fischer A, Onur S, Schmelzer C and Doring F (2012). "Ubiquinol decreases monocytic expression and DNA methylation of the pro-inflammatory chemokine ligand 2 gene in humans." *BMC Res Notes* 5: 540. [PubMed: 23021568]
- Franceschi C and Bonafe M (2003). "Centenarians as a model for healthy aging." *Biochem Soc Trans* 31(2): 457–461. [PubMed: 12653662]
- Frasch M, S. J, Metz G, Antonelli M (2017). "Animal models of fetal programming: Focus on chronic maternal stress during pregnancy and neurodevelopment" *Animal models for the study of human disease Elsevier Academic Press(Conn P Michael (Ed.). 2nd edition.*
- Frasch MG, Baier CJ, Antonelli MC and Metz GAS (2018). "Perinatal Psychoneuroimmunology: Protocols for the Study of Prenatal Stress and Its Effects on Fetal and Postnatal Brain Development." *Methods Mol Biol* 1781: 353–376. [PubMed: 29705857]
- Frasch MG, Burns P, Benito J, Cortes M, Cao M, Fecteau G and Desrochers A (2018). "Sculpting the Sculptors: Methods for Studying the Fetal Cholinergic Signaling on Systems and Cellular Scales." *Methods Mol Biol* 1781: 341–352. [PubMed: 29705856]
- Frasch MG, Liu HL, Cao M, MacDonald JW, Cortes M, Durosier LD, Burns P, Fecteau G, Desrochers A, Schulkin J, Antonelli MC, Dorschner M, & Bammler TK (2018). α 7 nicotinic acetylcholine receptor signaling modulates fetal sheep brain astrocytes transcriptome in response to endotoxin stress: Comparison to microglial transcriptome. Society for Neuroscience. San Diego, CA, 2018 Neuroscience Meeting Planner.
- Frasch MG, Lobmaier SM, Stampalija T, Desplats P, Pallares ME, Pastor V, Brocco MA, Wu HT, Schulkin J, Herry CL, Seely AJE, Metz GAS, Louzoun Y and Antonelli MC (2018). "Non-

invasive biomarkers of fetal brain development reflecting prenatal stress: An integrative multi-scale multi-species perspective on data collection and analysis.” *Neurosci Biobehav Rev*.

- Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM and Franceschi C (2017). “Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?” *Front Immunol* 8: 1960. [PubMed: 29375577]
- Garzoni L, Faure C and Frasch MG (2013). “Fetal cholinergic anti-inflammatory pathway and necrotizing enterocolitis: the brain-gut connection begins in utero.” *Front Integr Neurosci* 7: 57. [PubMed: 23964209]
- Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH and Kellis M (2015). “Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease.” *Nature* 518(7539): 365–369. [PubMed: 25693568]
- Gluckman PD and Hanson MA (2006). “The consequences of being born small - an adaptive perspective.” *Horm Res* 65 Suppl 3: 5–14. [PubMed: 16612108]
- Gluckman PD, Hanson MA and Mitchell MD (2010). “Developmental origins of health and disease: reducing the burden of chronic disease in the next generation.” *Genome Med* 2(2): 14. [PubMed: 20236494]
- Gomez-Gonzalez B and Escobar A (2010). “Prenatal stress alters microglial development and distribution in postnatal rat brain.” *Acta Neuropathol* 119(3): 303–315. [PubMed: 19756668]
- Gorelick PB (2010). “Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials.” *Ann N Y Acad Sci* 1207: 155–162. [PubMed: 20955439]
- Guillot-Sestier MV, Doty KR and Town T (2015). “Innate Immunity Fights Alzheimer’s Disease.” *Trends Neurosci* 38(11): 674–681. [PubMed: 26549882]
- Hanson MA, Cooper C, Aihie Sayer A, Eendebak RJ, Clough GF and Beard JR (2016). “Developmental aspects of a life course approach to healthy ageing.” *J Physiol* 594(8): 2147–2160. [PubMed: 26518329]
- Heim CM, Entringer S and Buss C (2019). “Translating basic research knowledge on the biological embedding of early-life stress into novel approaches for the developmental programming of lifelong health.” *Psychoneuroendocrinology* 105: 123–137. [PubMed: 30578047]
- Hemmerle AM, Herman JP and Seroogy KB (2012). “Stress, depression and Parkinson’s disease.” *Exp Neurol* 233(1): 79–86. [PubMed: 22001159]
- Heppner FL, Ransohoff RM and Becher B (2015). “Immune attack: the role of inflammation in Alzheimer disease.” *Nat Rev Neurosci* 16(6): 358–372. [PubMed: 25991443]
- Heurtaux T, Michelucci A, Losciuto S, Gallotti C, Felten P, Dorban G, Grandbarbe L, Morga E and Heuschling P (2010). “Microglial activation depends on beta-amyloid conformation: role of the formylpeptide receptor 2.” *J Neurochem* 114(2): 576–586. [PubMed: 20456016]
- Hoeijmakers L, Ruijgrok SR, Amelanchik A, Ivan D, van Dam AM, Lucassen PJ and Korosi A (2017). “Early-life stress lastingly alters the neuroinflammatory response to amyloid pathology in an Alzheimer’s disease mouse model.” *Brain Behav Immun* 63: 160–175. [PubMed: 28027926]
- Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ and Stevens B (2016). “Complement and microglia mediate early synapse loss in Alzheimer mouse models.” *Science* 352(6286): 712–716. [PubMed: 27033548]
- Hoyer D, Frasch MG, Eiselt M, Hoyer O and Zwiener U (2001). “Validating phase relations between cardiac and breathing cycles during sleep.” *IEEE Eng Med Biol Mag* 20(2): 101–106. [PubMed: 11321714]
- Hubacek JA, Pitha J, Podrapska I, Sochman J, Adamkova V, Lanska V and Poledne R (2000). “Insertion/deletion polymorphism in the angiotensin-converting enzyme gene in myocardial infarction survivors.” *Med Sci Monit* 6(3): 503–506. [PubMed: 11208361]
- Huizink AC, Mulder EJ and Buitelaar JK (2004). “Prenatal stress and risk for psychopathology: specific effects or induction of general susceptibility?” *Psychol Bull* 130(1): 115–142. [PubMed: 14717652]

- Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y and Hirsch EC (1996). "Nitric oxide synthase and neuronal vulnerability in Parkinson's disease." *Neuroscience* 72(2): 355–363. [PubMed: 8737406]
- Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M and Hashizume Y (2003). "Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains." *Acta Neuropathol* 106(6): 518–526. [PubMed: 14513261]
- Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hagg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Braekhus A, Brathen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbaek G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA and Posthuma D (2019). "Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk." *Nat Genet* 51(3): 404–413. [PubMed: 30617256]
- Jawahar MC, Murgatroyd C, Harrison EL and Baune BT (2015). "Epigenetic alterations following early postnatal stress: a review on novel aetiological mechanisms of common psychiatric disorders." *Clin Epigenetics* 7: 122. [PubMed: 26583053]
- Jellinger KA and Attems J (2013). "Neuropathological approaches to cerebral aging and neuroplasticity." *Dialogues Clin Neurosci* 15(1): 29–43. [PubMed: 23576887]
- Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, Bertelsen S, Goate AM and Cruchaga C (2014). "Coding variants in TREM2 increase risk for Alzheimer's disease." *Hum Mol Genet* 23(21): 5838–5846. [PubMed: 24899047]
- Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L and de Leon MJ (2008). "Inflammation and Alzheimer's disease: possible role of periodontal diseases." *Alzheimers Dement* 4(4): 242–250. [PubMed: 18631974]
- Kazlauskas N, Campolongo M, Lucchina L, Zappala C and Depino AM (2016). "Postnatal behavioral and inflammatory alterations in female pups prenatally exposed to valproic acid." *Psychoneuroendocrinology* 72: 11–21. [PubMed: 27337090]
- Kettenmann H, Hanisch UK, Noda M and Verkhratsky A (2011). "Physiology of microglia." *Physiol Rev* 91(2): 461–553. [PubMed: 21527731]
- Kim WG, Mohny RP, Wilson B, Jeohn GH, Liu B and Hong JS (2000). "Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia." *J Neurosci* 20(16): 6309–6316. [PubMed: 10934283]
- Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong JS, Beal MF and Joh TH (2007). "A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation." *FASEB J* 21(1): 179–187. [PubMed: 17116747]
- Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM and Lamb BT (2018). "Inflammation as a central mechanism in Alzheimer's disease." *Alzheimers Dement (N Y)* 4: 575–590. [PubMed: 30406177]
- Knott C, Stern G and Wilkin GP (2000). "Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2." *Mol Cell Neurosci* 16(6): 724–739. [PubMed: 11124893]
- Krohne HW (2001). "Stress and Coping Theories." *The International Encyclopedia of the Social and Behavioral Sciences* 22: 15163–15170.
- Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, Manalastas A, Hilfiker M, Pfister S, Schwerdel C, Riether C, Meyer U and Knuesel I (2012). "Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice." *J Neuroinflammation* 9: 151. [PubMed: 22747753]
- Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizzati A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier JG, Harold D, Fitzpatrick AL, Valladares O, Moutet ML, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi SH, Mateo

I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Vojnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernandez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamujic-Comic H, Frosch MP, Thonberg H, Maier W, Roschupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, Huebinger RM, Kilander L, Moebs S, Hernandez I, Kamboh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concarl L, Lord J, Beiser AS, Keene CD, Helisalimi S, Kloszewska I, Kukull WA, Koivisto AM, Lynch A, Tarraga L, Larson EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Solfrizzi V, Gill M, Longstreth WT Jr., Montine TJ, Frisardi V, Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman EM, Fievet N, Rotter JI, Reisch JS, Hanon O, Cupidi C, Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG, de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D, Wu CK, Soininen H, Avramidou D, Albin RL, Fratiglioni L, Germanou A, Apostolova LG, Keller L, Koutroumani M, Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D, Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela I, Carracedo A, Lannfelt L, Rubinsztein DC, Barnes LL, Pasquier F, Frolich L, Barral S, McGuinness B, Beach TG, Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM, Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD, Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ, McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ, Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C, Crocco EA, DeCarli C, Bisceglia G, Dick M, Ma L, Duara R, Graff-Radford NR, Evans DA, Hodges A, Faber KM, Scherer M, Fallon KB, Riemenschneider M, Fardo DW, Heun R, Farlow MR, Kolsch H, Ferris S, Leber M, Foroud TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hull M, Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K, Growdon JH, Feulner T, Hamilton RL, Harrell LE, Dricchel D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy A, Abner E, Menzies GE, Jin LW, Leonenko G, Real LM, Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G, Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer JH, Vardy E, LaFerla FM, Jockel KH, Lah JJ, Dichgans M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S, Lieberman AP, Klopp N, Lunetta KL, Wichmann HE, Lyketsos CG, Morgan K, Marson DC, Brown K, Martiniuk F, Medway C, Mash DC, Nothen MM, Masliah E, Hooper NM, McCormick WC, Daniele A, McCurry SM, Bayer A, McDavid AN, Gallacher J, McKee AC, van den Bussche H, Mesulam M, Brayne C, Miller BL, Riedel-Heller S, Miller CA, Miller JW, Al-Chalabi A, Morris JC, Shaw CE, Myers AJ, Wiltfang J, O'Bryant S, Olichney JM, Alvarez V, Parisi JE, Singleton AB, Paulson HL, Collinge J, Perry WR, Mead S, Peskind E, Cribbs DH, Rossor M, Pierce A, Ryan NS, Poon WW, Nacmias B, Potter H, Sorbi S, Quinn JF, Sacchinelli E, Raj A, Spalletta G, Raskind M, Caltagirone C, Bossu P, Orfei MD, Reisberg B, Clarke R, Reitz C, Smith AD, Ringman JM, Warden D, Roberson ED, Wilcock G, Rogava E, Bruni AC, Rosen HJ, Gallo M, Rosenberg RN, Ben-Shlomo Y, Sager MA, Mecocci P, Saykin AJ, Pastor P, Cuccaro ML, Vance JM, Schneider JA, Schneider LS, Slifer S, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tang M, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Welshmen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Saba Y, Alzheimer Disease Genetics C, European Alzheimer's Disease I, Cohorts for H, Aging C Research in Genomic Epidemiology, Genetic P Environmental Risk in Ad/Defining Genetic C Environmental Risk for Alzheimer's Disease, Pilotto A, Bullido MJ, Peters O, Crane PK, Bennett D, Bosco P, Coto E, Boccardi V, De Jager PL, Lleo A, Warner N, Lopez OL, Ingelsson M, Deloukas P, Chuchaga C, Graff C, Gwilliam R, Fornage M, Goate AM, Sanchez-Juan P, Kehoe PG, Amin N, Ertekin-Taner N, Berr C, Debette S, Love S, Launer LJ, Younkin SG, Dartigues JF, Corcoran C, Ikram MA, Dickson DW, Nicolas G, Champion D, Tschanz J, Schmidt H, Hakonarson H, Clarimon J, Munger R, Schmidt R, Farrer LA, Van Broeckhoven C, C. O. D. M. A. L. DeStefano, Jones L, Haines JL, Deleuze JF, Owen MJ, Gudnason V, Mayeux R, Escott-Price V, Psaty BM, Ramirez A, Wang LS, Ruiz A, van Duijn CM, Holmans PA, Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert JC and Pericak-Vance MA (2019). "Genetic meta-analysis

of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing." *Nat Genet* 51(3): 414–430. [PubMed: 30820047]

- Labrousse VF, Leyrolle Q, Amadiou C, Aubert A, Sere A, Coutureau E, Gregoire S, Bretillon L, Pallet V, Gressens P, Joffre C, Nadjar A and Laye S (2018). "Dietary omega-3 deficiency exacerbates inflammation and reveals spatial memory deficits in mice exposed to lipopolysaccharide during gestation." *Brain Behav Immun* 73: 427–440. [PubMed: 29879442]
- Lahiri DK, Maloney B and Zawia NH (2009). "The LEARN model: an epigenetic explanation for idiopathic neurobiological diseases." *Mol Psychiatry* 14(11): 992–1003. [PubMed: 19851280]
- Le Page A, Dupuis G, Frost EH, Larbi A, Pawelec G, Witkowski JM and Fulop T (2018). "Role of the peripheral innate immune system in the development of Alzheimer's disease." *Exp Gerontol* 107: 59–66. [PubMed: 29275160]
- Lee M, Cho T, Jantarotnotai N, Wang YT, McGeer E and McGeer PL (2010). "Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases." *FASEB J* 24(7): 2533–2545. [PubMed: 20228251]
- Lesuis SL, van Hoek B, Lucassen PJ and Krugers HJ (2017). "Early postnatal handling reduces hippocampal amyloid plaque formation and enhances cognitive performance in APP^{sw}/PS1^{dE9} mice at middle age." *Neurobiol Learn Mem* 144: 27–35. [PubMed: 28579367]
- Levine ME, Lu AT, Bennett DA and Horvath S (2015). "Epigenetic age of the prefrontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning." *Aging (Albany NY)* 7(12): 1198–1211. [PubMed: 26684672]
- Li JJ, Li Q, Du HP, Wang YL, You SJ, Wang F, Xu XS, Cheng J, Cao YJ, Liu CF and Hu LF (2015). "Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter." *Int J Mol Sci* 16(6): 12560–12577. [PubMed: 26047341]
- Liddel SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B and Barres BA (2017). "Neurotoxic reactive astrocytes are induced by activated microglia." *Nature* 541(7638): 481–487. [PubMed: 28099414]
- Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS and Carvey PM (2002). "In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain." *Mov Disord* 17(1): 116–124. [PubMed: 11835448]
- Ling ZD, Chang Q, Lipton JW, Tong CW, Landers TM and Carvey PM (2004). "Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain." *Neuroscience* 124(3): 619–628. [PubMed: 14980732]
- Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekblom A, Svenningsson P, Chen H and Wirdefeldt K (2017). "Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study." *Neurology* 88(21): 1996–2002. [PubMed: 28446653]
- Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, Menger MD and Fassbender K (2012). "TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation." *J Immunol* 188(3): 1098–1107. [PubMed: 22198949]
- Lobmaier S, M. A, Zelgert C, Shen C, Su P-C, Schmidt G, Haller B, Berg G, Fabre B, Weyrich J, Wu H, Frasnich M, Antonelli M (2019). "Fetus: the radar of maternal stress, a cohort study." *Quantitative Biology > Quantitative Methods* arXiv:1902.09746v1 [q-bio.QM].
- Luo XG, Ding JQ and Chen SD (2010). "Microglia in the aging brain: relevance to neurodegeneration." *Mol Neurodegener* 5: 12. [PubMed: 20334662]
- Madhusudan A, Vogel P and Knuesel I (2013). "Impact of prenatal immune system disturbances on brain development." *J Neuroimmune Pharmacol* 8(1): 79–86. [PubMed: 22580757]
- Manucha W (2017). "Mitochondrial dysfunction associated with nitric oxide pathways in glutamate neurotoxicity." *Clin Investig Arterioscler* 29(2): 92–97.
- Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, Wray NR and Visscher PM

(2018). “GWAS on family history of Alzheimer’s disease.” *Transl Psychiatry* 8(1): 99. [PubMed: 29777097]

- Marrocco J, Mairesse J, Ngomba RT, Silletti V, Van Camp G, Bouwalerh H, Summa M, Pittaluga A, Nicoletti F, Maccari S and Morley-Fletcher S (2012). “Anxiety-like behavior of prenatally stressed rats is associated with a selective reduction of glutamate release in the ventral hippocampus.” *J Neurosci* 32(48): 17143–17154. [PubMed: 23197707]
- Mastorci F, Vicentini M, Viltart O, Manghi M, Graiani G, Quaini F, Meerlo P, Nalivaiko E, Maccari S and Sgoifo A (2009). “Long-term effects of prenatal stress: changes in adult cardiovascular regulation and sensitivity to stress.” *Neurosci Biobehav Rev* 33(2): 191–203. [PubMed: 18771688]
- Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD and Rogers J (2010). “Epigenetic changes in Alzheimer’s disease: decrements in DNA methylation.” *Neurobiol Aging* 31(12): 2025–2037. [PubMed: 19117641]
- Mastroeni D, Sekar S, Nolz J, Delvaux E, Lunnon K, Mill J, Liang WS and Coleman PD (2018). “Correction: ANK1 is up-regulated in laser captured microglia in Alzheimer’s brain; the importance of addressing cellular heterogeneity.” *PLoS One* 13(1): e0191382. [PubMed: 29324907]
- Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Champion A, McBride HM, Gruenheid S, Trudeau LE and Desjardins M (2019). “Intestinal infection triggers Parkinson’s disease-like symptoms in *Pink1(-/-)* mice.” *Nature* 571(7766): 565–569. [PubMed: 31316206]
- McDonnell-Dowling K and Miczek KA (2018). “Alcohol, psychomotor-stimulants and behaviour: methodological considerations in preclinical models of early-life stress.” *Psychopharmacology (Berl)* 235(4): 909–933. [PubMed: 29511806]
- McGeer PL, Itagaki S, Boyes BE and McGeer EG (1988). “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains.” *Neurology* 38(8): 1285–1291. [PubMed: 3399080]
- Meda L, Cassatella MA, Szendrei GI, Otvos L Jr., Baron P, Villalba M, Ferrari D and Rossi F (1995). “Activation of microglial cells by beta-amyloid protein and interferon-gamma.” *Nature* 374(6523): 647–650. [PubMed: 7715705]
- Metz GA, Ng JW, Kovalchuk I and Olson DM (2015). “Ancestral experience as a game changer in stress vulnerability and disease outcomes.” *Bioessays* 37(6): 602–611. [PubMed: 25759985]
- Modgil S, Lahiri DK, Sharma VL and Anand A (2014). “Role of early life exposure and environment on neurodegeneration: implications on brain disorders.” *Transl Neurodegener* 3: 9. [PubMed: 24847438]
- Moretti R and Caruso P (2019). “The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice.” *Int J Mol Sci* 20(1).
- Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, Koyanagi K and Hoon DS (2005). “Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.” *Cancer Res* 65(5): 1800–1807. [PubMed: 15753377]
- Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y, Wang Y, Ushijima T, Baba T, Shibuya K, Shibuya A, Kawabe Y and Yanagisawa J (2006). “A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory.” *EMBO J* 25(5): 1081–1092. [PubMed: 16498406]
- Nerius M, Doblhammer G and Tamguney G (2019). “GI infections are associated with an increased risk of Parkinson’s disease.” *Gut*.
- Noda M (2016). “Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration.” *Curr Alzheimer Res* 13(4): 381–386. [PubMed: 26567741]
- Okada T, Matsuzaki N, Sawai K, Nobunaga T, Shimoya K, Suzuki K, Taniguchi N, Saji F and Murata Y (1997). “Chorioamnionitis reduces placental endocrine functions: the role of bacterial lipopolysaccharide and superoxide anion.” *J Endocrinol* 155(3): 401–410. [PubMed: 9487985]
- Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D and Gross CT (2011). “Synaptic pruning by microglia is necessary for normal brain development.” *Science* 333(6048): 1456–1458. [PubMed: 21778362]

- Peters A, McEwen BS and Friston K (2017). “Uncertainty and stress: Why it causes diseases and how it is mastered by the brain.” *Prog Neurobiol* 156: 164–188. [PubMed: 28576664]
- Pocernich CB and Butterfield DA (2012). “Elevation of glutathione as a therapeutic strategy in Alzheimer disease.” *Biochim Biophys Acta* 1822(5): 625–630. [PubMed: 22015471]
- Post MR, Lieberman OJ and Mosharov EV (2018). “Can Interactions Between alpha-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson’s Disease?” *Front Neurosci* 12: 161. [PubMed: 29593491]
- Querfurth HW and LaFerla FM (2010). “Alzheimer’s disease.” *N Engl J Med* 362(4): 329–344. [PubMed: 20107219]
- Ramos EA, Grochoski M, Braun-Prado K, Seniski GG, Cavalli IJ, Ribeiro EM, Camargo AA, Costa FF and Klassen G (2011). “Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.” *PLoS One* 6(12): e29461. [PubMed: 22220212]
- Ransohoff RM and Brown MA (2012). “Innate immunity in the central nervous system.” *J Clin Invest* 122(4): 1164–1171. [PubMed: 22466658]
- Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M, Liang WS, Beckmann ND, Price ND, Reiman EM, Schadt EE, Ehrlich ME, Gandy S and Dudley JT (2018). “Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus.” *Neuron* 99(1): 64–82 e67. [PubMed: 29937276]
- Reitz C, Tang MX, Miller J, Green R and Luchsinger JA (2009). “Plasma homocysteine and risk of mild cognitive impairment.” *Dement Geriatr Cogn Disord* 27(1): 11–17. [PubMed: 19088473]
- Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C, Tusche MW, Pavlov VA, Andersson U, Chavan S, Mak TW and Tracey KJ (2011). “Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit.” *Science* 334(6052): 98–101. [PubMed: 21921156]
- Santos SF, de Oliveira HL, Yamada ES, Neves BC and Pereira A Jr. (2019). “The Gut and Parkinson’s Disease-A Bidirectional Pathway.” *Front Neurol* 10: 574. [PubMed: 31214110]
- Sawada M, Imamura K and Nagatsu T (2006). “Role of cytokines in inflammatory process in Parkinson’s disease.” *J Neural Transm Suppl*(70): 373–381.
- Schaafsma W, Basterra LB, Jacobs S, Brouwer N, Meerlo P, Schaafsma A, Boddeke E and Eggen BJJ (2017). “Maternal inflammation induces immune activation of fetal microglia and leads to disrupted microglia immune responses, behavior, and learning performance in adulthood.” *Neurobiol Dis* 106: 291–300. [PubMed: 28751257]
- Schaefer AT and Teuchert-Noodt G (2016). “Developmental neuroplasticity and the origin of neurodegenerative diseases.” *World J Biol Psychiatry* 17(8): 587–599. [PubMed: 23705632]
- Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA and Stevens B (2012). “Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner.” *Neuron* 74(4): 691–705. [PubMed: 22632727]
- Schwarz JM, Hutchinson MR and Bilbo SD (2011). “Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression.” *J Neurosci* 31(49): 17835–17847. [PubMed: 22159099]
- Scott Kelso, J. A, Holt KG, Rubin P and Kugler PN (1981). “Patterns of human interlimb coordination emerge from the properties of non-linear, limit cycle oscillatory processes.” *J Mot Behav* 13(4): 226–261.
- Sen N (2015). “Epigenetic regulation of memory by acetylation and methylation of chromatin: implications in neurological disorders, aging, and addiction.” *Neuromolecular Med* 17(2): 97–110. [PubMed: 24777294]
- Slusarczyk J, Trojan E, Glombik K, Budziszewska B, Kubera M, Lason W, Popiolek-Barczyk K, Mika J, Wedzony K and Basta-Kaim A (2015). “Prenatal stress is a vulnerability factor for altered morphology and biological activity of microglia cells.” *Front Cell Neurosci* 9: 82. [PubMed: 25814933]
- Smith AD, Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, Miller JW, Rosenberg IH and Obeid R (2018). “Homocysteine and Dementia: An International Consensus Statement.” *J Alzheimers Dis* 62(2): 561–570. [PubMed: 29480200]

- Smith AR, Smith RG, Condliffe D, Hannon E, Schalkwyk L, Mill J and Lunnon K (2016). "Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer's disease brain." *Neurobiol Aging* 47: 35–40. [PubMed: 27522519]
- Smith LM and Strittmatter SM (2017). "Binding Sites for Amyloid-beta Oligomers and Synaptic Toxicity." *Cold Spring Harb Perspect Med* 7(5).
- Southwick S, C. D (2012). "Resilience. The Science of Mastering Life's Greatest Challenges." Conference Proceedings.
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R and Goedert M (1997). "Alpha-synuclein in Lewy bodies." *Nature* 388(6645): 839–840. [PubMed: 9278044]
- Stephan AH, Barres BA and Stevens B (2012). "The complement system: an unexpected role in synaptic pruning during development and disease." *Annu Rev Neurosci* 35: 369–389. [PubMed: 22715882]
- Suh HS, Choi S, Khattar P, Choi N and Lee SC (2010). "Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes." *J Neuroimmune Pharmacol* 5(4): 521–532. [PubMed: 20157787]
- Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L and Masliah E (1998). "Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders." *Am J Pathol* 152(2): 367–372. [PubMed: 9466562]
- Tang Y and Le W (2016). "Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases." *Mol Neurobiol* 53(2): 1181–1194. [PubMed: 25598354]
- Urduingio RG, Sanchez-Mut JV and Esteller M (2009). "Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies." *Lancet Neurol* 8(11): 1056–1072. [PubMed: 19833297]
- Van den Bergh BR (2011). "Developmental programming of early brain and behaviour development and mental health: a conceptual framework." *Dev Med Child Neurol* 53 Suppl 4: 19–23.
- Van den Bergh BRH, van den Heuvel MI, Lahti M, Braeken M, de Rooij SR, Entringer S, Hoyer D, Roseboom T, Raikkonen K, King S and Schwab M (2017). "Prenatal developmental origins of behavior and mental health: The influence of maternal stress in pregnancy." *Neurosci Biobehav Rev*.
- Velazquez R, Ferreira E, Winslow W, Dave N, Piras IS, Naymik M, Huentelman MJ, Tran A, Caccamo A and Oddo S (2019). "Maternal choline supplementation ameliorates Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations." *Mol Psychiatry*.
- von Bernhardi R, Eugenin-von Bernhardi L and Eugenin J (2015). "Microglial cell dysregulation in brain aging and neurodegeneration." *Front Aging Neurosci* 7: 124. [PubMed: 26257642]
- Wang A, Costello S, Cockburn M, Zhang X, Bronstein J and Ritz B (2011). "Parkinson's disease risk from ambient exposure to pesticides." *Eur J Epidemiol* 26(7): 547–555. [PubMed: 21505849]
- Wang Y, Ma Y, Hu J, Zhang X, Cheng W, Jiang H, Li M, Ren J, Zhang X, Liu M, Sun A, Wang Q and Li X (2016). "Sex-specific effects of prenatal chronic mild stress on adult spatial learning capacity and regional glutamate receptor expression profiles." *Exp Neurol* 281: 66–80. [PubMed: 27094122]
- Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB and Chesselet MF (2012). "Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein." *Exp Neurol* 237(2): 318–334. [PubMed: 22750327]
- Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G, Wagner J, Hasler LM, Wild K, Skodras A, Blank T, Staszewski O, Datta M, Centeno TP, Capece V, Islam MR, Kerimoglu C, Staufenbiel M, Schultze JL, Beyer M, Prinz M, Jucker M, Fischer A and Neher JJ (2018). "Innate immune memory in the brain shapes neurological disease hallmarks." *Nature* 556(7701): 332–338. [PubMed: 29643512]
- Wessels I, Haase H, Engelhardt G, Rink L and Uciechowski P (2013). "Zinc deficiency induces production of the proinflammatory cytokines IL-1beta and TNFalpha in promyeloid cells via epigenetic and redox-dependent mechanisms." *J Nutr Biochem* 24(1): 289–297. [PubMed: 22902331]

- Williamson LL, Chao A and Bilbo SD (2012). "Environmental enrichment alters glial antigen expression and neuroimmune function in the adult rat hippocampus." *Brain Behav Immun* 26(3): 500–510. [PubMed: 22281279]
- Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L and Lucius R (2003). "Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease." *FASEB J* 17(3): 500–502. [PubMed: 12631585]
- Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H and Przedborski S (2002). "Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease." *J Neurosci* 22(5): 1763–1771. [PubMed: 11880505]
- Wu Z and Nakanishi H (2014). "Connection between periodontitis and Alzheimer's disease: possible roles of microglia and leptomeningeal cells." *J Pharmacol Sci* 126(1): 8–13. [PubMed: 25168594]
- Xie F, Zhao Y, Ma J, Gong JB, Wang SD, Zhang L, Gao XJ and Qian LJ (2016). "The involvement of homocysteine in stress-induced Abeta precursor protein misprocessing and related cognitive decline in rats." *Cell Stress Chaperones* 21(5): 915–926. [PubMed: 27435080]
- Xu H, Gelyana E, Rajsombath M, Yang T, Li S and Selkoe D (2016). "Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid beta-Protein Oligomers." *J Neurosci* 36(35): 9041–9056. [PubMed: 27581448]
- Yam KY, Schipper L, Reemst K, Ruigrok SR, Abbink MR, Hoeijmakers L, Naninck EFG, Zarekiani P, Oosting A, Van der Beek EM, Lucassen PJ and Korosi A (2019). "Increasing availability of omega-3 fatty acid in the early-life diet prevents the early-life stress-induced cognitive impairments without affecting metabolic alterations." *FASEB J* 33(4): 5729–5740. [PubMed: 30673509]
- Yau YH and Potenza MN (2013). "Stress and eating behaviors." *Minerva Endocrinol* 38(3): 255–267. [PubMed: 24126546]
- Yin Z, Raj D, Saiepour N, Van Dam D, Brouwer N, Holtman IR, Eggen BJJ, Moller T, Tamm JA, Abdourahman A, Hol EM, Kamphuis W, Bayer TA, De Deyn PP and Boddeke E (2017). "Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer's disease." *Neurobiol Aging* 55: 115–122. [PubMed: 28434692]
- Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, Su X, Liu J, Ge W, Levine RL, Li N and Cao X (2015). "Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6." *Nature* 525(7569): 389–393. [PubMed: 26287468]
- Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS and Zhang J (2005). "Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease." *FASEB J* 19(6): 533542.
- Zou CG, Zhao YS, Gao SY, Li SD, Cao XZ, Zhang M and Zhang KQ (2010). "Homocysteine promotes proliferation and activation of microglia." *Neurobiol Aging* 31(12): 2069–2079. [PubMed: 19131143]
- Zuena AR, Mairesse J, Casolini P, Cinque C, Alema GS, Morley-Fletcher S, Chiodi V, Spagnoli LG, Gradini R, Catalani A, Nicoletti F and Maccari S (2008). "Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats." *PLoS One* 3(5): e2170. [PubMed: 18478112]

Highlights

- Susceptibility to Parkinson's and Alzheimer's is programmed in utero
- Chronic pregnancy stress and inflammation exert impact via microglial plasticity
- We review key mechanisms mediating microglial plasticity and neurodevelopment
- We discuss early postnatal preventive measures that can reduce the risk




Figure 1. Spatiotemporal integration of prenatal stress and the accompanying or independently occurring systemic- and neuro-inflammation on glial energy reserves that may modulate the risk for neurodegeneration via modulation of the pace or extent of immunosenescence.

(1), maternal-fetal circulation as an example of the interface for stress or inflammation/ infection transfer of endogenous or exogenous biological mediators such as stress hormones, cytokines, bacteria or viruses (other interfaces are known for transfer of maternal exposures onto the fetus such as direct bacterial ascension into the fetal compartment or maternal-fetal heart rate entrainment which is likely biophysical). These factors induce or modulate changes in microglia in the fetal brain mediated by epigenetic changes (2).

(3), cogwheel representation of interlocking, spatiotemporally (across organs/systems and during fetal/child growth and adulthood) distributed effectors which together shape the individual phenotype of the adult brain

(4), over a sequence of repetitive, potentially asymptomatic modifications in (1) - (3); child and adult neuro- and glial development are shaped with variable degrees of susceptibility to neurodegeneration.